Delaware
|
001-34079
|
11-3516358
|
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
|
20850
|
|
Rockville, MD | ||
(Address of principal executive offices)
|
(Zip Code)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 | Regulation FD Disclosure. |
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
Exhibit No. | Description |
99.1 | Rexahn Pharmaceuticals, Inc. press release dated February 4, 2015, announcing the appointment of Ely Benaim, M.D., as Chief Medical Officer. |
REXAHN PHARMACEUTICALS, INC.
|
|
Date: February 4, 2015
|
/s/ Tae Heum Jeong
|
Tae Heum Jeong
|
|
Senior Vice President of Finance and Chief Financial Officer
|
Exhibit No. | Description |
99.1 | Rexahn Pharmaceuticals, Inc. press release dated February 4, 2015, announcing the appointment of Ely Benaim, M.D., as Chief Medical Officer. |